Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 8:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Fluoruracil Clear all
Completed Phase 1Phase 2 Interventional

Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer

NCT00625651
View directory record Official record
Conditions
Metastatic Colorectal Cancer, Colon Cancer, Colorectal Cancer, Rectal Cancer
Interventions
Placebo, AMG 655, Modified FOLFOX6, Bevacizumab
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
61
States / cities
Hot Springs, Arkansas • Downey, California • La Jolla, California + 56 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2014 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

Combination Chemotherapy Plus Radiation Therapy Followed By Surgery in Treating Patients With Stage I, Stage II, or Stage III Esophageal Cancer

NCT00006472
View directory record Official record
Conditions
Esophageal Cancer
Interventions
carboplatin, fluorouracil, paclitaxel, conventional surgery, radiation therapy
Drug · Procedure · Radiation
Lead sponsor
Medstar Health Research Institute
Other
Eligibility
Up to 120 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2002
U.S. locations
6
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2020 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Comparison of Combination Chemotherapy Regimens in Treating Patients With Advanced Stomach Cancer

NCT00003172
View directory record Official record
Conditions
Gastric Cancer
Interventions
filgrastim, recombinant interferon alfa, docetaxel, doxorubicin hydrochloride, fluorouracil, hydroxyurea
Biological · Drug
Lead sponsor
Eastern Cooperative Oncology Group
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2004
U.S. locations
24
States / cities
Denver, Colorado • Chicago, Illinois • Peoria, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 23, 2026, 8:14 PM EDT
Completed No phase listed Observational

Proximal Molecular Effects of Concurrent Chemoradiotherapy on Head and Neck Squamous Cell Carcinoma

NCT00620139
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma
Interventions
the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,
Biological
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2013 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

Chemotherapy With Raltitrexed and Fluorouracil in Treating Patients With Advanced Colorectal Cancer

NCT00002828
View directory record Official record
Conditions
Colorectal Cancer
Interventions
fluorouracil, raltitrexed
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2001
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Trial of Tivantinib With FOLFOX for the Treatment of Advanced Solid Tumors and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal Junction or Stomach

NCT01611857
View directory record Official record
Conditions
Malignant Solid Tumour, Gastroesophageal Cancer
Interventions
Tivantinib, FOLFOX
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
9
States / cities
New Haven, Connecticut • Fort Myers, Florida • Sarasota, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 22, 2016 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional

SU5416 in Treating Patients With Metastatic Kidney Cancer That Has Not Responded to Previous Treatment

NCT00009919
View directory record Official record
Conditions
Recurrent Renal Cell Cancer, Stage IV Renal Cell Cancer
Interventions
semaxanib
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
16 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2013 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1Phase 2 Interventional

CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

NCT03699319
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
Drug
Lead sponsor
David Bajor, MD
Other
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 22, 2025 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

FDG-PET Directed Treatment in Improving Response in Patients With Locally Advanced Stomach or Gastroesophageal Junction Cancer

NCT02485834
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Gastric Adenocarcinoma, Gastric Cancer
Interventions
FDG-PET, surgery, 5-FU, capecitabine, docetaxel, Irinotecan, 3D-CRT, IMRT
Procedure · Drug · Radiation
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
71
States / cities
Los Angeles, California • St. Helena, California • Newark, Delaware + 47 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2025 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Phase 2a Study of BAX69 and 5-FU/Leucovorin or Panitumumab Versus Standard of Care in Subjects With Metastatic Colorectal Cancer

NCT02448810
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BAX69 + infusional 5-FU/LV, BAX69 + panitumumab, BAX69 + 5-FU/LV, Standard of Care, Standard of Care
Biological · Drug
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
12
States / cities
Port Saint Lucie, Florida • Joliet, Illinois • Goshen, Indiana + 9 more
Source: ClinicalTrials.gov public record
Updated May 24, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Not yet recruiting No phase listed Observational

5-Fluorouracil and Calcipotriene for Field Treatment of Actinic Keratoses

NCT07794059
View directory record Official record
Conditions
Actinic Keratoses
Interventions
Combination field therapy with 5-fluorouracil and calcipotriene (5FU/C)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Early Phase 1 Interventional

Concurrent Chemoradiation + 5-FU + Mitomycin-C in Anal Carcinoma

NCT01858025
View directory record Official record
Conditions
Carcinoma of the Anal Canal
Interventions
Pencil Beam scanning Radiation, 5-fluorouracil, Mitomycin-C
Radiation · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma

NCT01652976
View directory record Official record
Conditions
Pancreatic Cancer Metastatic
Interventions
Dasatinib, mFOLFOX6
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2 Interventional Results available

Study of 5-FU, Oxaliplatin, & Lapatinib Combined With Radiation Therapy to Treat HER2 Positive Esophagogastric Cancer

NCT01769508
View directory record Official record
Conditions
HER2 Positive Esophagogastric Cancer
Interventions
5-Fluorouracil, Oxaliplatin, Lapatinib, Radiation Therapy
Drug · Radiation
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
9
States / cities
Fort Myers, Florida • Orlando, Florida • Pensacola, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2016 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

S1201: Combination Chemo for Patients W/Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Cancer

NCT01498289
View directory record Official record
Conditions
Adenocarcinoma of the Gastroesophageal Junction, Esophageal Cancer, Gastric Cancer
Interventions
FOLFOX regimen, docetaxel, fluorouracil, irinotecan hydrochloride, leucovorin calcium, oxaliplatin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2019
U.S. locations
508
States / cities
Mobile, Alabama • Little Rock, Arkansas • Auburn, California + 320 more
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional

Irinotecan and Cyclosporine in Treating Patients With Metastatic, Advanced or Locally Recurrent Colorectal Cancer

NCT00003950
View directory record Official record
Conditions
Colorectal Cancer
Interventions
cyclosporine, CPT-11
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2005
U.S. locations
10
States / cities
Chicago, Illinois • Decatur, Illinois • Evanston, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 6, 2014 · Synced Sep 23, 2026, 8:14 PM EDT
Recruiting Phase 1 Interventional

A Study of ASP2138 Given Before Surgery, Then Chemotherapy After Surgery, in People With Pancreatic Ductal Cancer

NCT07024615
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma
Interventions
ASP2138, Oxaliplatin, Leucovorin, 5-FU, Irinotecan, Gemcitabine, Nab-paclitaxel, Capecitabine
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
3
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 1, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Combination Chemotherapy and Bevacizumab in Treating Patients With Advanced Neuroendocrine Tumors

NCT00227617
View directory record Official record
Conditions
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Lung Cancer, Neoplastic Syndrome, Neuroendocrine Tumor
Interventions
bevacizumab, 5-fluorouracil, leucovorin, oxaliplatin
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2016
U.S. locations
2
States / cities
San Francisco, California • Vallejo, California
Source: ClinicalTrials.gov public record
Updated May 21, 2023 · Synced Sep 23, 2026, 8:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer

NCT07049055
View directory record Official record
Conditions
Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma
Interventions
E-EDV-D682, EDV-GC, Gemcitabine, Nab paclitaxel.
Drug
Lead sponsor
Engeneic Pty Limited
Industry
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
El Segundo, California • Summit, New Jersey • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 1 Interventional

A Study to Evaluate Immunotherapy Combinations in Participants With Gastrointestinal Malignancies

NCT03720678
View directory record Official record
Conditions
GastroEsophageal Cancer, Colorectal Cancer
Interventions
etrumadenant, mFOLFOX
Drug
Lead sponsor
Arcus Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Tucson, Arizona • Denver, Colorado • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Sep 23, 2026, 8:14 PM EDT
Recruiting Phase 3 Interventional

Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer

NCT07228832
View directory record Official record
Conditions
Metastatic Colorectal Cancer (CRC)
Interventions
Drug: Ivonescimab Injection, Drug: Bevacizumab Injection
Drug
Lead sponsor
Summit Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
102
States / cities
Mobile, Alabama • Tuscaloosa, Alabama • Goodyear, Arizona + 85 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Recruiting Phase 1Phase 2 Interventional

Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel

NCT06483555
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer, Basal Cell Neoplasm
Interventions
Gemcitabine, Nab paclitaxel, Erlotinib, NALIRIFOX, Folfirinox
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Sep 23, 2026, 8:14 PM EDT
Not listed Not applicable Interventional

Fluorouracil, External-Beam Radiation Therapy, and Gemcitabine With or Without Brachytherapy Using Phosphorus P32 in Treating Patients With Locally or Regionally Advanced Unresectable Adenocarcinoma of the Pancreas

NCT00079365
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
fluorouracil, gemcitabine hydrochloride, brachytherapy, phosphorus P32, radiation therapy
Drug · Radiation
Lead sponsor
University of South Florida
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 3, 2013 · Synced Sep 23, 2026, 8:14 PM EDT
Completed Phase 2 Interventional Results available

Phase II Trial of Pembrolizumab With Trastuzumab and Chemotherapy in Advanced HER2 Positive Esophagogastric (EG) Cancer

NCT02954536
View directory record Official record
Conditions
Esophageal Cancer, Gastric Cancer
Interventions
pembrolizumab, trastuzumab, capecitabine, cisplatin, Oxaliplatin, 5-Fluorouracil
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 15, 2023 · Synced Sep 23, 2026, 8:14 PM EDT